Introduction
Aurora kinases are a family of highly conserved serinethreonine protein kinases that have a key role in several stages of mitosis. The three family members are Aurora A, B and C. Aurora A and B expression is intimately related to the proliferation of most cells and their cellular localization is highly dynamic during mitosis ( Figure 1 ). The gene for Aurora A, AURKA, maps to chromosome region 20q13.2 and transfection studies in rodent fibroblasts have demonstrated it to be a bona fide oncogene. 1 Aurora A has an important role in centrosome maturation, spindle assembly, meiotic maturation and metaphase I spindle orientation.
1 Aurora A function is regulated by degradation, phosphorylation and dephosphorylation, with its kinase activity being dependent upon phosphorylation of threonine 288 (Thr288) in the activation loop. 1 Selective inhibition of Aurora A results in inhibition of autophosphorylation of Aurora A at Thr288, inhibition of p53 phosphorylation, monopolar spindles and G2-M arrest. 2, 3 Human Aurora B kinase forms a chromosomal passenger complex (CPC) with three non-enzymatic subunits: inner centromere protein, survivin and borealin. 4 The highly dynamic CPC is critical for chromosome condensation, chromosome orientation on the mitotic spindle and the spindle-assembly checkpoint as well as the final stages of cytokinesis.
1 Aurora B is the key component of the CPC, with inhibition of Aurora B resulting in impaired CPC function. 4 Aurora B phosphorylates the inner centromere protein, survivin and borealin; moreover, Aurora B activity and localization during mitosis is tightly regulated by its complex interaction with these CPC partners. 4 Phosphorylation of the inner centromere protein by Aurora B induces a conformational change that, in turn, facilitates Aurora B phosphorylation and full activation of the kinase. 4 Survivin phosphorylation at threonine 117 by Aurora B is involved in regulating localization, while the functional result of borealin phosphorylation is unclear. 4 Aurora B also phosphorylates histone H3 at serine 10 and 28 during mitosis, implicating Aurora B in chromosome condensation. 1 Selective inhibition of Aurora B classically results in polyploidy (X4 N DNA content due to DNA replication without cell division), inhibition of histone H3 phosphorylation at serine 10 and apoptosis. 2, 3 Inhibition of phosphorylated histone H3 has also proved useful in the clinic as a mechanism of action biomarker for inhibition of Aurora B. 3 The gene for Aurora B, AURKB, maps to chromosome region 17p13.1. Aurora C expression appears to be limited to the testis, where its role has not been well defined, although there is recent data showing Aurora C protein expression in human leukemia cell lines with siRNA knockdown of Aurora C resulting in increased p27Kip1 and decreased Skp2 levels, G0/G1 arrest, apoptosis and growth inhibition of leukemia cells. 1, 6 Over-expression, amplification and polymorphisms of the Aurora kinase genes, particularly Aurora A, have been documented for a wide range of solid tumors, with some studies showing correlations between expression, amplification and polymorphisms with disease status, survival and cancer risk. 5, 7 Although studies in leukemia have been limited to cell lines and small patient cohorts, over-expression of Aurora A has been consistently demonstrated, while the expression of Aurora B in leukemia is reported to be variable. [8] [9] [10] [11] To date there is no evidence to correlate expression or amplification of Aurora kinases and prognosis in leukemia.
An oncogenic role for Aurora A was first identified a decade ago and henceforth there has been increasing interest in targeting Aurora kinases in a diverse range of malignant diseases, including leukemia. 5, 12, 13 Aurora kinase inhibitors developed to date bind to the kinase ATP binding site, as do all of the small-molecule kinase inhibitors in therapeutic use; for example, imatinib.
14 Aurora kinase inhibitors are generally regarded as being pan-Aurora inhibitors or selective inhibitors for either Aurora A or Aurora B. Similar to other kinase inhibitors, however, most Aurora kinase inhibitors developed thus far also inhibit a range of 'off-target' kinases such as ABL, JAK2 and FLT3 to varying degrees. Consistent with their ability to inhibit ABL and FLT3, the most promising hematological application for Aurora kinase inhibitors appears to be in Philadelphia chromosome-positive (Ph þ ) leukemias and FLT3-mutated acute myeloid leukemia (AML), respectively. This review aims to summarize the evidence supporting the utility of Aurora kinase inhibitors in these disease groups and discuss the toxicity profile seen in clinical trials to date.
Ph þ leukemias
Chronic myeloid leukemia (CML) and Ph þ acute lymphoblastic leukemia (Ph þ ALL) have been a hematological focus of Aurora kinase inhibitor research owing to the ability of a number of compounds to overcome tyrosine kinase inhibitor (TKI) resistance, particularly when arising from the T315I mutation of the ABL kinase domain, a common mutation in patients treated with imatinib. 15 Collectively, point mutations of the ABL kinase domain occur in approximately 43% of Ph þ patients treated with TKI therapy, with the highest rates of mutation seen in those with blast-crisis CML (CML BC ) or Phþ ALL; the relative frequency of the T315I mutation is also much higher in these patients. 16 A recent review of T315I-positive patients has also demonstrated that compared with CML patients in the chronic (CML CP ) or accelerated phase (CML AP ), patients with CML BC and Ph þ ALL have the T315I mutation detected earlier after starting TKI therapy and have lower disease-free and overall survival rates. 17 Aurora kinase inhibitors currently undergoing clinical trial in patients with CML or Ph þ ALL are summarized in Table 1 . One of the first reports of the activity of Aurora kinase inhibitors in Ph þ leukemia involved the pan-Aurora kinase inhibitor MK-0457 (previously known as VX-680), which was studied in three adult patients with T315I ABL-mutated CML (n ¼ 2) or Ph þ ALL (n ¼ 1). 18 MK-0457 was administered as a continuous infusion for 5 days at 2 to 3-weekly intervals. Inhibition of CrkL phosphorylation (a nuclear adaptor and transcriptional activator in BCR-ABL-positive cells) 19 was only evident when peak plasma concentrations of MK-0457 were greater than 1 mM, with this concentration achieved only at doses of at least 20 mg/m 2 /h. Reversible pancytopenia was the only reported toxicity. 18 A phase II trial of MK-0457 in patients with T315I mutant CML and Ph þ ALL opened in January 2007, followed by a MK-0457 has now been replaced by MK-5108 (previously VX-689); this compound is currently being assessed in a phase I study of patients with solid tumors. 20, 21 It has not yet been disclosed whether MK-5108 maintains efficacy against ABL kinase or whether it is in clinical trial in CML or Ph þ ALL. The issue of QTc prolongation is discussed further in the section on clinical toxicity.
The pan-Aurora, ABL, FLT3 and JAK2 kinase inhibitor AT9283 has also recently entered clinical trials, with activity reported in patients with refractory AML and CML. 22 Two patients with CML AP refractory to imatinib and dasatinib experienced hematological responses, one of which also had a partial cytogenetic response. 22 Pharmacodynamic studies demonstrated a reduction in phosphorylation of histone H3, CrkL and STAT5, suggesting multi-kinase inhibition. 22 It should be noted that as STAT5 phosphorylation is downstream of ABL, FLT3 and JAK2 signalling, 15, 23, 24 it is unclear which kinase target was primarily responsible for STAT5 inhibition by AT9283. Doselimiting toxicities included elevated transaminases, non-cardiac creatine kinase and lactate dehydrogenase rises, tumor lysis syndrome, myelosuppression and alopecia. The maximum tolerated dose of AT9283 as a 72-h intravenous infusion was 108 mg/m 2 /day. 22 Although the ABL mutation status of the two CML patients was not reported, murine xenograft studies using BCR-ABL (T315I and E255K) transfected BaF3 cells and primary patient samples (E255K mutated) have demonstrated the in vivo efficacy of AT9283 against ABL mutants.
25
Danusertib (PHA-739358), a pan-Aurora and ABL inhibitor, is currently being evaluated in a phase I study of patients with advanced stage CML (CML BC or CML AP ) or Ph þ ALL resistant or intolerant of imatinib or second-generation TKI therapy. 26 Danusertib is given as a 3-h intravenous infusion for 7 consecutive days every 2 weeks and the MTD is yet to be determined. Twenty-three patients have been treated (11 Ph þ ALL, 8 CML BC , 4 CML AP ), with 15 patients having confirmed a T315I mutation. Six patients have responded, including three cytogenetic (one complete, one partial, one minimal) and five hematological responses, and one clinical improvement (reduction in extramedullary disease mass). 26 The multi-kinase inhibitor XL228, targeting Aurora A, ABL, IGF-1R, SRC and LYN, is currently being evaluated in phase I studies in patients with refractory leukemia. In 27 patients with CML and Ph þ ALL, 10 of which had the T315I mutation, XL228, administered as a 1-h infusion once or twice weekly, was reportedly well tolerated although transient dose-related increases in glucose and insulin occurred, consistent with inhibition of IGF-1R and IR. 27 Objective responses have been demonstrated for patients receiving at least 3.6 mg/kg, including those with a T315I mutation, with decreased white blood cell counts and/or 41 log reductions in BCR-ABL levels. 27 
Mechanism of ABL inhibition
A number of Aurora kinase inhibitors with activity against ABL kinase are more active against the mutated kinase isoforms than the wild type ( Table 2 ). The crystallography of VX-680 (MK-0457) bound to the imatinib-resistant H396P mutated kinase demonstrates that the binding mode clearly accommodates the T315I mutation. 28 Modugno et al. 29 subsequently reported the X-ray co-crystal structure of PHA-739358 (danusertib) bound to the T315I mutated ABL kinase domain, showing that the compound occupies the ATP-binding pocket in an active conformation of the mutated kinase.
In addition to the T315I mutation of ABL, the dasatinibresistant V299L mutation has been shown to develop in the context of dasatinib therapy as second-line sequential treatment for imatinib-resistant CML. 30 Curiously, the V299L mutation regains sensitivity for imatinib but is also sensitive in vitro to VX-680 (MK-0457). 30 Shah et al. 30 correctly hypothesized that VX-680's (MK-0457) affinity for ABL may be enhanced by the V299L mutation, as V299 is a contact residue on ABL for both dasatinib and VX-680 (MK-0457), and the corresponding residue on Aurora A is leucine. Thus, off-target activities of Aurora kinase inhibitors in clinical trial may provide benefit to CML and/or Ph þ ALL patients who develop resistance to firstand second-line TKI therapy.
What are the key biochemical targets in Ph þ leukemias: Aurora kinases, ABL kinases or both?
An obvious biological question that has not been fully answered is whether inhibition of Aurora kinases, ABL kinases or both families is required for efficacy in wild-type and ABL-mutated CML/Ph þ ALL. Aurora kinase inhibitors such as MK-0457, danusertib and AT9283, with efficacy in Ph þ leukemia, clearly inhibit both Aurora and ABL signalling, whereas imatinib does not inhibit phosphorylation of the classic Aurora B downstream mechanistic biomarker, histone H3. 22, 28, 31 In TKI-resistant cells, including T315I mutants, ABL signalling is inhibited by Aurora kinase inhibitors but not by imatinib or dasatinib. 28, 31 Preclinical studies of danusertib have also demonstrated dosedependent inhibition of BCR-ABL, with BCR-ABL inhibition occurring at lower concentrations than those required for Aurora inhibition. 32 Finally, murine BaF3 cells have been shown to be less sensitive to MK-0457 than BaF3 cells ectopically expressing either wild-type or mutant BCR-ABL. 33 Conflicting evidence using the Aurora/ABL inhibitor AS703569 on similar BaF3 cells has recently been reported. 34 Low doses of AS703569, which were anti-proliferative and pro-apoptotic, induced a phenotype consistent with inhibition of Aurora B, but did not inhibit BCR-ABL. 34 It should also be noted that preclinical studies have demonstrated synergistic cytotoxicity for danusertib with imatinib and for MLN8237 with the TKI nilotinib. 31, 35 Although synergistic, whether the enhanced cytotoxicity is primarily due to increased BCR-ABL inhibition or the additional Aurora kinase Aurora kinase inhibitors in leukemia AS Moore et al Table 2 Aurora, FLT3 and ABL kinase profiles of Aurora, FLT3 and tyrosine kinase inhibitors inhibition remains unclear. Combination therapy of this type has the potential to reduce the emergence of imatinib-resistant cell lines, but more clinical experience with Aurora kinase inhibitors in large trials of TKI-resistant disease will need to be established before combination trials can be considered. 32 In addition, the efficacy of selective Aurora kinase inhibitors in this disease area remains to be tested.
Finally, the role of JAK2 inhibition in myeloproliferative diseases with and without the BCR-ABL translocation remains unclear. 36 Some Aurora kinase inhibitors such as AT9283 show potent inhibition of JAK2 (IC 50 ¼ 1.2 nM) . 22 The therapeutic implications of concomitantly inhibiting Aurora, ABL and JAK2 are yet to be fully described; however, as JAK2 is required for normal hematopoiesis, myelosuppression may be an important adverse effect. 23 As discussed in the section on clinical toxicity, myelosuppression has been reported in phase I trials of AT9283. 22 Acute myeloid leukemia A number of Aurora kinase inhibitors developed to date are also potent inhibitors of FLT3 kinase (Table 2) . Not surprisingly, a number of first-generation FLT3 inhibitors, including CEP-701 and PKC-412, have recently been shown to bind Aurora A and B kinases with high affinity. 37 Consistent with this kinaseinhibitory profile, pre-clinical and clinical data to date suggest that Aurora kinase inhibitors are more active in FLT3-mutated AML compared with FLT3 wild-type AML. 10, [38] [39] [40] Aurora kinase inhibitors currently under clinical trial in patients with AML are summarized in Table 3 . AT9283 is active against Aurora A (52% inhibition at 3 nM), Aurora B (58% inhibition at 3 nM), T315I ABL (IC 50 ¼ 4 nM) and JAK2 (IC 50 ¼ 1.2 nM). 22 The anti-FLT3 activity is also relatively potent (57% kinase inhibition at 15 nM; Table 2) , 22 suggesting that all five targets may be equivalently inhibited at similar concentrations, depending upon how in vitro kinase inhibitory potency translates into cellular and in vivo inhibition for each kinase. Seven of 23 reported AML patients enrolled in the current phase I/IIa trial of AT9283 in refractory leukemia have experienced a reduction in marrow blasts.
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AS703569 is similarly potent across Aurora A, Aurora B, FLT3 and ABL kinases; 40 this compound is currently in a phase I study of patients with primary AML (n ¼ 20), secondary AML (n ¼ 13), CML (n ¼ 6), myelodysplastic syndrome (n ¼ 5) and myeloproliferative disease (n ¼ 1), with objective responses seen in patients with CML (T315I mutant), AML and myelodysplastic syndrome. Frequently observed toxicities include neutropenia, thrombocytopenia, infection, mucositis and diarrhea, but the final maximal tolerated dose is yet to be defined. 41 The results of a phase I/II study of the Aurora B selective compound AZD1152 were recently reported. 42 Thirty-two patients have been treated in each phase of the trial, with a mean age of 66 years (range 45-82) in part A and 68 years (range 48-87) in part B. 42 For the two parts of the study combined, the overall clinical response rate was 23%, including three complete remissions, all in patients treated at the maximum tolerated dose of 1200 mg. 42 The number of patients with FLT3 mutations in the trial was not specified in the abstract and the activity of AZD1152 against FLT3 kinase has not been published. All patients in both parts of the study experienced an adverse event, with over one-third experiencing fatigue (41%), febrile neutropenia (38%) or stomatitis (38%). 42 What are the key biochemical targets in AML: Aurora kinases, FLT3 kinase or both?
Although classified for clinical trial purposes as a FLT3 inhibitor (IC 50 6.6 nM), KW-2449 could be classified as a multi-kinase inhibitor, with IC 50 values for Aurora and ABL also being less than 50 nM (Table 2) . 43 Pre-clinical studies demonstrated the activity of KW-2449 against the AML cell lines (MOLM-13 and MV-4-11), reducing phosphorylated FLT3 and STAT5. 43 Both these cell lines harbor internal tandem duplications of FLT3 (FLT3-ITD). 44 Furthermore, FLT3 wild-type cells (RS-4-11) were sensitive to KW-2449, consistent with the activity by inhibition of Aurora kinases as demonstrated by reduced phosphorylation of histone H3, G2/M arrest and apoptosis. The extent of Aurora inhibition in the MOLM-13 cells and FLT3 inhibition in the RS-4-11 cells was not reported. 43 Of great interest are the recent results of a phase I trial of KW-2449 in AML patients, which used the plasma inhibitory activity assay to monitor ex vivo inhibition of FLT3 as a secondary end point. 45 Data from preclinical studies have shown that continuous exposure to FLT3 inhibitors at concentrations sufficient to continually abrogate FLT3 autophosphorylation to 10-20% of baseline is required for cytotoxicity. 45 Although FLT3 inhibition occurred in the phase I study of KW-2449, FLT3 phosphorylation was only transiently inhibited to levels less than 20% of baseline. On the basis of these elegant pharmacodynamic findings, and before the maximal tolerated dose was determined, the trial was stopped early and a new study with a modified dosing strategy was planned. 45 The degree to which markers of Aurora inhibition, such as phosphorylated histone H3, were inhibited by KW-2449 was not reported. Thus, further pharmacokinetic/pharmacodynamic linked efficacy studies on KW-2449 are required to determine whether this agent can deliver therapeutic efficacy in AML and whether any such efficacy is consistent with inhibition of FLT3 kinase, Aurora kinases or both.
The differential effects of Aurora A and B inhibition by the dual inhibitor AT9283 have recently been reported by Goodall et al. 46 Using a panel of AML cell lines with or without mutations of ras, FLT3 and c-kit, two phenotypes were apparent. Those cells driven by mutations of ras, FLT3 or c-kit showed G2/M arrest followed by apoptosis, characteristic of Aurora A inhibition, while other cells developed 44 N DNA content and polyploidy followed by apoptosis consistent with Aurora B inhibition. 46 The authors speculate that such difference in response may be related to differential expression of Aurora A and B, as well as mutations of p53 and genetic instability in these cell lines. 46 The pan-Aurora and FLT3 inhibitor R763/AS703569 has been shown to inhibit a panel of AML cell lines, including MV-4-11 and HL-60, with the FLT3-ITD mutated MV-4-11 being 10-fold more sensitive than other cell lines and an MV-4-11 xenograft model being more sensitive than an HL-60 (FLT3 wild-type) xenograft model. Sustained inhibition of both FLT3 and histone H3 phosphorylation was seen in tumor lysates up to 48 h after the final dose of 15 mg/kg per day. 40 The greater sensitivity of FLT3-ITD cells is consistent with inhibition of FLT being a critical component of the anti-tumor efficacy of AS703569. 47 Two of the most specific FLT3 inhibitors developed to date, AC220 and tandutinib (MLN-518), have very low binding affinity for Aurora A, B and C kinases. 37 The efficacy of these compounds against FLT3-mutated AML provides support to the hypothesis that inhibition of FLT3 alone, when FLT3 is constitutively activated, is sufficient to cause cell death. The additional benefit of Aurora inhibition may become important in the setting of FLT3-inhibitor resistance. It has been demonstrated that survivin is over-expressed in pre-clinical models of FLT3-inhibitor resistance. 24 As Aurora B couples with and phosphorylates survivin in the CPC, it is possible that inhibition of Aurora B could overcome FLT3-inhibitor resistance by impairing CPC function. This hypothesis is yet to be explored.
Clinical toxicity profile of Aurora kinase inhibitors
As with any new agent in hemato-oncology, the predictability of therapy-related toxicity is vital for their safe introduction into clinical practice. Although not exhaustive, important and common toxicities experienced to date with Aurora kinase inhibitors are discussed below.
Myelosuppression and general cytotoxicity
Among the most frequent adverse events experienced to date with the Aurora kinase inhibitors are myelosuppression, febrile neutropenia and gastrointestinal events such as nausea, diarrhea and mucositis. Such adverse events have been reported for leukemia trials of AT9283, danusertib, XL-228, AS703569 and AZD1152. 22, 26, 27, 41, 42 It is worth noting that in a recent phase I study of danusertib with and without granulocyte colony stimulating factor (G-CSF) support in patients with solid tumors, the recommended phase II dose was 50% higher with G-CSF (750 mg/m 2 ) than the maximum tolerated phase I dose without G-CSF (500 mg/m 2 ). 48 Gastrointestinal bleeding has also been reported with AS703569 and one patient treated with AT9283 has developed tumor lysis syndrome. 22, 41 The cellular effects of Aurora B inhibition and the toxicity profile of the selective Aurora B inhibitor AZD1152 suggest that myelosuppression and other general cytotoxic effects such as mucositis are consequences of Aurora B inhibition. In contrast, in a recent phase I study of the highly selective FLT3 inhibitor AC220, the most common possibly drug-related adverse events reported were grade 2 or less, including gastrointestinal events, peripheral edema and dysgeusia. 49 The extent to which offtarget JAK2 inhibition by Aurora kinase inhibitors causes myelosuppression is unknown.
Cardiovascular
The QTc prolongation experienced with MK-0457 is not a class effect of the Aurora kinase inhibitors. A diverse range of drugs can inhibit the human ether-a-go-go related gene (hERG) channel, leading to prolongation of the QTc interval. A great deal of effort is put into eliminating hERG inhibition early in the process of drug development, and although the predictive value of preclinical testing is greater than 80%, it is not infallible. 50 Other cardiac events reported to date in leukemia patients include hypertension with AT9283 and bradycardia with XL228. 22, 27 Potential late effects
Although the acute toxicity profile of Aurora kinase inhibitors seems to be manageable, consideration should be given to the potential late effects of these new agents. The potential late effects arising from Aurora C inhibition on spermatogenesis and fertility need to be addressed. Concern has also been raised about the long-term effects of Aurora kinase inhibitors on breast tissue, as polyploidy has been induced in normal mammary epithelial cell cultures. 5, 51 Given that Aurora kinase expression is highest during mitosis, 1 the effects on more quiescent cells such as hematopoietic stem cells should be minimal. However, in vitro and in vivo murine xenograft studies using human cord blood cells revealed dose-dependent effects of AZD1152 on growth and proliferation, although after drug removal surviving cells continued to proliferate and produce colonies, indicating that non-malignant progenitor cells are sensitive to Aurora B inhibition but can survive treatment and, furthermore, might be resistant to re-exposure with AZD1152. 52 Whether or not such surviving progenitors are then more likely to undergo malignant transformation needs to be addressed.
Conclusions
The unique off-target kinase profiles of many Aurora kinase inhibitors developed to date make them attractive agents for the treatment of acute myeloid and Ph þ leukemias. Provided the toxicity profile of these Aurora kinase inhibitors is predictable and manageable, one clear indication for these new agents may be in the setting of TKI-resistant and T315I mutant Ph þ leukemias. Whether upfront combination therapy with a resistance-prone TKI will be useful in managing the emergence of resistance remains to be tested. The efficacy of highly selective Aurora kinase inhibitors that do not inhibit ABL is yet to be evaluated in Ph þ leukemias.
For AML, the evidence to date suggests that inhibition of FLT3 is a critical component of efficacy in FLT3-ITD cell lines. Dual Aurora and FLT3 kinase inhibitors may provide therapeutic benefit in FLT3-mutated AML, and the inhibition of Aurora B could overcome FLT3-inhibitor resistance by impairing CPC function. The general cytotoxic effects of Aurora kinase inhibition may also be useful in non-FLT3 mutated AML, but efficacy in this clinical setting is yet to be fully tested.
